AZ, Bicycle pair up to develop bicyclic peptides
AstraZeneca and Bicycle Therapeutics have entered into a deal to develop bicyclic peptides that could net the latter firm more than $1 billion if all pre-specified targets are met.
Read More
Tag: bicyclic peptides
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
